stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) Revenue
BioMarin Pharmaceutical Inc.'s revenue for fiscal 2025 was $3.2B, up 12.9% from $2.9B in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.7B. Over the past ten years it has ranged from $889.9M (fiscal 2015) to $3.2B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. BioMarin Pharmaceutical Inc. ranks 9th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.2B | 12.87% |
| FY2024 | $2.9B | 17.97% |
| FY2023 | $2.4B | 15.42% |
| FY2022 | $2.1B | 13.53% |
| FY2021 | $1.8B | (0.76%) |
| FY2020 | $1.9B | 9.18% |
| FY2019 | $1.7B | 14.27% |
| FY2018 | $1.5B | 13.52% |
| FY2017 | $1.3B | 17.62% |
| FY2016 | $1.1B | 25.50% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.0B | 3.53% |
| Jun 2026 | $989.7M | 29.17% |
| Mar 2026 | $766.2M | (12.39%) |
| Dec 2025 | $874.6M | 12.68% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. | $3.7B |
| TECH Bio-Techne Corp compare | $1.2B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| TGTX TG Therapeutics, Inc. compare | $799.5M |
| TWST Twist Bioscience Corporation compare | $431.8M |
| IBRX ImmunityBio, Inc. compare | $165.8M |
| KYMR Kymera Therapeutics, Inc. compare | $105.0M |
| SMMT Summit Therapeutics PLC compare | $705.0K |
| PCVX Vaxcyte, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BMRN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement